[#DIV28SUPER] Postdoctoral Fellowships Announcement, Virginia Tech, Addiction Recovery Research Center

A postdoctoral position is available in Addiction Research Recovery Research Center at the Virginia Tech Carilion Research Institute.  The position will contribute to NIDA, NIAAA, NCI, and NIDDK funded research studies employing behavioral economics and neuro-economic approaches to address addiction or obesity and its treatment using both human laboratory and clinical trial methodologies.  This position will have the opportunity to participate in studies using our International Quit and Recovery Registry, employing neuro-modulatory (TMS) and fMRI technologies.  Applicants should be interested in pursuing a career in addiction or obesity research, be an effective and productive writer, and have research training in clinical, experimental, cognitive psychology or related fields. Applicants must have completed a Ph.D.  Translational research training and career development opportunities are provided as part of this position. The successful candidate will collaborate with a dynamic, productive federally funded, multi-disciplinary team of researchers. Women and minorities are strongly encouraged to apply. Applications will be reviewed on an ongoing basis. The position will be open until filled. Submit a letter of interest and curriculum vitae and referees to Warren K. Bickel, Ph.D.  wkbickel@vtc.vt.edu

 

-- 

 
Warren K. Bickel, Ph.D. 

Director,

Addiction Recovery Research Center, 

Virginia Tech Carilion Research Institute 

Professor of Psychology, Virginia Tech

Professor of Health Sciences, Virginia Tech

Professor of Psychiatry, Virginia Tech Carilion  School of Medicine

 

Virginia Tech Carilion Research Institute
2 Riverside Circle
Roanoke, VA, 24016

Email: wkbickel@vt.edu
Tel: 540 526 2088

Fax:  540-985-3361 

 

International Quit & Recovery Website:

https://quitandrecovery.org/

 

 

[#DIV28SUPER] Postdoctoral Fellowships Announcement, University of New Mexico, Center on Alcoholism, Substance Abuse, and Addictions

The Center on Alcoholism, Substance Abuse, and Addictions (CASAA) announces one new postdoctoral position on our NIAAA Institutional Research Training grant. The goal of the grant is to prepare future NIH scientists to conduct research to (1) elucidate the processes of change in drinking behavior, (2) develop and test effective methods to effect change through self-change, treatment and indicated prevention, and (3) develop and test models to disseminate knowledge of effective interventions to diverse populations. The grant supports four predoctoral fellows in the Department of Psychology and three postdoctoral fellows who may come from any discipline relevant to the goals of the training program. Fellows work with one of the core training faculty: Barbara S. McCrady (PI and training program director), Eric Claus, Tim Condon, Jon Houck, Theresa Moyers, Matthew Pearson, J. Scott Tonigan, Kamilla Venner, Katie Witkiewitz, or W. Gill Woodall.

 

We have at least one opening to support a postdoctoral fellow. Applicants must meet the following criteria: (1) demonstrated interest in the alcohol field as evidenced by prior coursework, research, and/or clinical experience; (2) a record of research productivity as evidenced by research presentations and peer-reviewed publications; and (3) a commitment to a career in alcohol research. All fellows must be US citizens or permanent resident aliens.

 

As part of the training program, fellows must be engaged in full-time research training, participate in a weekly Addictions seminar, define a training plan and achieve specific competencies during each year, and limit outside employment. For continued support post-doctoral fellows will be expected to prepare and successfully submit an NIH grant application.  The training program provides a NIH-defined stipend (based on years since doctoral degree), tuition remission, support for professional travel up to $2000 per year, and support for training- and research-related expenses.  

 

Interested applicants should submit a curriculum vitae, 3 letters of recommendation, 1-page statement of interest, letter stating their qualifications for and interest in the training grant, and their graduate transcripts to Barbara McCrady. Applications will be reviewed on a rolling basis, but preference will be given to applications received by January 15, 2016.  Submit all materials electronically to: 

 

Barbara S. McCrady, Ph.D.

Distinguished Professor of Psychology

Director, Center on Alcoholism, Substance Abuse, and Addictions (CASAA)

University of New Mexico

2650 Yale Blvd. SE

Albuquerque, NM 87106

bmccrady@unm.edu

 

See http://casaa.unm.edu/traininggrant.html for information about the training program

 

 

[#DIV28SUPER] Faculty Position in Health Disparities at Auburn University

Attached is an ad for an Associate Professor position in Psychology at Auburn University in Health Disparities. The area is broadly defined but investigators interested in disparities in prevention, diagnosis or treatment of behavioral disorders are encouraged to apply.

 

This is a cluster hire, so the position in Psychology is one of several being advertised.  A key, and very exciting, component of this position is the opportunity to collaborate with others in Pharmacy, Nursing, Human Development, and Nutrition.  

The rank is expected to be at the Associate Professor level and a record of publication and funding is expected.

 

 

Please feel free to forward and to contact me with any questions.

 

 

--------------------------------------------------------------------------
Chris Newland, Ph. D.

Professor, Department of Psychology                          

226 Thach Hall 

342 West Thach Concourse     
Auburn University

Alabama 36849-5212
Office: 334 844-6479      Fax:     334 844-4447
www.auburn.edu/~newlamc/PersonalWeb

---------------------------------------------------------------------------

 

[#DIV28M] FW: [CPDD] Action Required: WHO International Ketamine Rescheduling

Please see below for something that is likely of interest to Division 28 members.
-Bill.

               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
phone: (859) 257-5383
facsimile: (859) 257-7684

Associate Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
University of Kentucky Center for Clinical and Translational Science

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

---

From: College on Problems of Drug Dependence [CPDD@LISTS.VCU.EDU] on behalf of Connie Pollack [cayladati@GMAIL.COM]
Sent: Friday, October 09, 2015 10:46 AM
To: CPDD@LISTS.VCU.EDU
Subject: [CPDD] Action Required: WHO International Ketamine Rescheduling

Dear Member,

Click Here to View Online

October 8, 2015 Action Required: WHO International Ketamine Rescheduling   The World Health Organization (WHO) is considering a change to the international scheduling of ketamine, proposed by China. YOUR ACTION IS NEEDED to ask the FDA to protect doctors' and veterinarians' access to this critical drug. Elevating international regulation of ketamine as a Schedule 1 drug could mean that it will be very difficult, if not impossible, for U.S. practitioners to use.   On October 5, the U.S. Food and Drug Administration (FDA) issued a request for comments regarding the abuse potential, actual abuse, medical usefulness, trafficking and impact of scheduling changes on the availability for medical use of 10 drug substances – including ketamine. The comments, DUE THURSDAY, OCTOBER 15, will be considered as FDA prepares a response to the WHO regarding the abuse liability and diversion of these drugs and will be provided to the 36th Expert Committee on Drug Dependence (ECDD), which will meet in Geneva November 16-20.   NABR has drafted a letter to the FDA that generally explains how critical ketamine is to veterinary and human medicine and how important it is that it remain accessible to biomedical research. We encourage you to use this template as a starting point to submit your own letter to the FDA. Below are the question(s) WHO has asked be addressed in your response:   • Ketamine use in clinical settings - when is ketamine the anesthetic, sedative or analgesic agent of choice for any of the following: emergency situations; conducting procedures with pediatric patients; short surgical procedures; long surgical procedures; surgery conducted outside a hospital without respiratory support facilities; and other.   • Veterinary therapeutic indications approved for ketamine (choices offered: anesthesia; pain management; sedation; no approved uses; other).    • Current use of ketamine in medical or scientific research (including clinical trials).    Comments can be filed at Regulations.gov.

NABR | 1100 Vermont Avenue, NW, Suite 1100| Washington, DC 20005 | Tel 202.857.0540 | Fax 202.659.1902 | info@nabr.org

 

___________________________ CPDD@lists.vcu.edu moderated member announcements
College on Problems of Drug Dependence web site CPDDblog list archives
Enable CPDD-talk, a discussion list for: existing members new members
Click to signoff or signoff by email

[#DIV28SUPER] Comments on NIDA Draft Strategic Plan

Dear Colleagues,

 

As APA considers commenting on NIDA’s Draft Strategic Plan, I would appreciate hearing from Division 28 and 50 members to better understand how well the draft reflects (or doesn’t) the science you’re interested in.  What’s laudable? What’s missing? What’s overemphasized? What’s under-represented?

 

Comments are due October 27 and I’m hoping to synthesize input starting the week of the 19^th, so if possible, please send me your thoughts between now and then.  Thanks very much for your help.

 

Best,

-geoff

 

Geoffrey K. Mumford, Ph.D. | Associate Executive Director for Government Relations Science Directorate American Psychological Association 750 First Street NE, Washington, DC 20002-4242 Tel: 202.336.6067 |  Fax: 202.336.6063 email: gmumford@apa.org | www.apa.org
P Most people consider the environment before printing their email.

 

 

 

 

 

[#DIV28SUPER] NIDA Reorganization to Integrate Its Research Portfolio, Promote Translational Research, and Increase Efficiencies

Dear Colleagues and Investigators:

 

As many of you already know, over the past few months, the National Institute on Drug Abuse (NIDA) has been working on a reorganization (http://www.drugabuse.gov/news-events/news-releases/2015/10/translational-research-focus-nida-organizational-shift)  of its Divisional Structure to integrate its basic and clinical research portfolio, promote translational research, and increase efficiencies. The new  structure (http://www.drugabuse.gov/about-nida/organization)   which will go into effect on October 1, 2015, will eliminate the Division of Clinical Neuroscience and Behavior (DCNBR), and incorporate its scientific portfolio on clinical neuroscience, brain development, and behavioral treatment development into existing and newly formed components of other NIDA divisions.  As part of this process, staff will also be moving to different divisions within NIDA, and there is a possibility that your assigned Program Officer and Grants Management (GM) specialist will be changed.  These modifications will be updated in the electronic Research Administration (eRA) Commons system, and we expect to have them completed by November 15, 2015.   We ask that you please log in to your eRA Commons (https://public.era.nih.gov/commons/public/login.do) account at that time, and confirm your NIH program official and GM specialist. 

 

Should you desire additional information or have any immediate questions, please feel free to contact your current Program Officer.

NIDA is excited about the new scientific opportunities that this reorganization will bring.  With your continued support, we will continue to advance the science of drug abuse and addiction as well as promote translational research across the Institute. 

 

Sincerely,

 

Susan Weiss, Ph.D.

Director, Division of Extramural Research

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contactjpollock@mail.nih.gov     301-435-1309

[#DIV28SUPER] NYTimes: Behaviorists Show the U.S. How to Improve Government Operations

http://www.nytimes.com/2015/09/30/business/behaviorists-show-the-us-how-to-improve-government-operations.html?smid=nytcore-ipad-share&smprod=nytcore-ipad

A year-old effort by the Obama administration is applying academic research on human behavior to the business of running the government.


Sent from my iPad
_____________________ div28SUPER@lists.apa.org _____________________
Div28m members #div28 subscribers corner: http://lists.apa.org